GlassScriptPhysician profile
Aziz N Chami
NPI 1578672507
$5,581.53
in general payments reported to CMS, 2019-2025
29 companies · $1,210 in 2025
The $1,210 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $272 · 2021: $334 · 2022: $1,142 · 2023: $965 · 2024: $1,212 · 2025: $1,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,347 · Education: $39.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,346.68 |
| Education | $39.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $848.63 | 2019-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $712.94 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $708.39 | 2019-2025 | Tavneos |
| Otsuka America Pharmaceutical, INC. | $642.47 | 2019-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $588.49 | 2019-2025 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $475.03 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $217.67 | 2022-2025 | Lupkynis |
| Travere Therapeutics, INC. | $213.43 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $142.98 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $139.88 | 2021-2025 | Arexvy, Benlysta, Jesduvroq |
| Ardelyx, INC. | $120.37 | 2024-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $106.30 | 2024-2025 | |
| Horizon Therapeutics Plc | $103.45 | 2019-2023 | Procysbi, Krystexxa |
| Ani Pharmaceuticals, INC. | $76.67 | 2023-2024 | Purified Cortrophin Gel |
| Lilly USA, LLC | $65.62 | 2023-2025 | Jardiance |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $63.20 | 2021-2024 | Terlivaz |
| Opko Pharmaceuticals, LLC | $48.44 | 2022-2025 | Rayaldee |
| Kyowa Kirin, INC. | $40.36 | 2023-2025 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $34.82 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.46 | 2022 | |
| Alexion Pharmaceuticals, INC. | $30.54 | 2021-2023 | Strensiq |
| Akebia Therapeutics INC | $29.58 | 2024 | Vafseo, Auryxia |
| Alnylam Pharmaceuticals INC. | $28.95 | 2023 | Oxlumo |
| Mallinckrodt Enterprises LLC | $25.23 | 2019 | |
| Apellis Pharmaceuticals, INC. | $19.88 | 2025 | |
| Nxstage Medical, INC. | $17.81 | 2024 | |
| Daiichi Sankyo INC. | $17.09 | 2020 | |
| Pfizer INC. | $14.53 | 2023 | |
| Merck Sharp & Dohme LLC | $14.32 | 2024 | Prevymis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aziz Chami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.